GnRH agonists, antagonists, and assisted conception

Seminars in Reproductive Medicine

Volumn 20, Issue 4, 2002, Pages 349-364

  Van Loenen, André C D ^a   Huirne, Judith A F ^a   Schats, Roel ^a   Hompes, Peter G A ^a   Lambalk, Cornelis B ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Agonist; Antagonist; Assisted reproduction; GnRH; IUI; IVF

Indexed keywords

ABARELIX; AZALINE B; BUSERELIN; CETRORELIX; DESLORELIN; FOLLITROPIN; GANIRELIX; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN RECEPTOR; GONADOTROPIN; GOSERELIN; HISTRELIN; ITURELIX; LEUPRORELIN; LUTEINIZING HORMONE; NAFARELIN; NAFARELIN ACETATE; ORAL CONTRACEPTIVE AGENT; PLACEBO; SUPERCUR; SUPRAFACT; TEVERELIX; TRIPTORELIN; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; GONADOTROPIN RELEASE; HUMAN; HYPOPHYSIS; INFERTILITY THERAPY; LUTEINIZATION; LUTEINIZING HORMONE RELEASE; OVARY CYST; REVIEW; SIDE EFFECT;

FERTILIZATION; FERTILIZATION IN VITRO; GONADOTROPIN-RELEASING HORMONE; HUMANS; REPRODUCTIVE TECHNIQUES; SAFETY;

EID: 0036869865     PISSN: 15268004     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-36713     Document Type: Review

References (179)

1. Edwards RG. The history of assisted human conception with especial reference to endocrinology. Exp Clin Endocrinol Diabetes 1996;104:183-204
2. Janssens RM, Lambalk CB, Vermeiden JP, et al. Dose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: A prospective, randomized, double-blind, placebo-controlled study. Hum Reprod 2000;15:2333-2340
3. Templeton A, Morris JK. Reducing the risk of multiple births by transfer of two embryos after in vitro fertilization. N Engl J Med 1998;339:573-577
4. Porter RN, Smith W, Craft IL, Abdulwahid NA, Jacobs HS. Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins. Lancet 1984;2:1284-1285
5. Schally AV, Nair RM, Redding TW, Arimura A. Isolation of the luteinizing hormone and follicle-stimulating hormone-releasing hormone from porcine hypothalami. J Biol Chem 1971;246:7230-7236
6. Amos M, Burgus R, Blackwell R, Vale W, Fellows R, Guillemin R. Purification, amino acid composition and N-terminus of the hypothalamic luteinizing hormone releasing factor (LRF) of bovine origin. Biochem Biophys Res Commun 1971;44:205-210
7. Sealfon SC, Weinstein H, Millar RP. Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Endocr Rev 1997;18:180-205
8. Yahalom D, Chen A, Ben Aroya N, et al. The gonadotropin-releasing hormone family of neuropeptides in the brain of human, bovine and rat: Identification of a third isoform. FEBS Lett 1999;463:289-294
9. Yang-Feng TL, Seeburg PH, Francke U. Human luteinizing hormone-releasing hormone gene (LHRH) is located on short arm of chromosome 8 (region 8p11.2-p21). Somat Cell Mol Genet 1986;12:95-100
10. White RB, Eisen JA, Kasten TL, Fernald RD. Second gene for gonadotropin-releasing hormone in humans. Proc Natl Acad Sci U S A 1998;95:305-309
11. Probst JC, Skutella T, Muller-Schmid A, Jirikowski GF, Hoffmann W. Molecular and cellular analysis of rP1.B in the rat hypothalamus: In situ hybridization and immunohistochemistry of a new P-domain neuropeptide. Brain Res Mol Brain Res 1995;33:269-276
12. Kottler ML, Lorenzo F, Bergametti F, Commercon P, Souchier C, Counis R. Subregional mapping of the human gonadotropin-releasing hormone receptor (GnRH-R) gene to 4q between the markers D4S392 and D4S409. Hum Genet 1995;96:477-480
13. Millar R, Lowe S, Conklin D, et al. A novel mammalian receptor for the evolutionarily conserved type II GnRH. Proc Natl Acad Sci U S A 2001;98:9636-9641
14. Neill JD, Duck LW, Sellers JC, Musgrove LC. A gonadotropin-releasing hormone (GnRH) receptor specific for GnRH II in primates. Biochem Biophys Res Commun 2001;282:1012-1018
15. Janssens RM, Brus L, Cahill DJ, Huirne JA, Schoemaker J, Lambalk CB. Direct ovarian effects and safety aspects of GnRH agonists and antagonists. Hum Reprod Update 2000;6:505-518
16. Stojilkovic SS, Reinhart J, Carr KJ. Gonadotropin-releasing hormone receptors: Structure and signal transduction pathways. Endocr Rev 1994;15:462-499
17. Kaiser UB, Conn PM, Chin WW. Studies of gonadotropin-releasing hormone (GnRH) action using GnRH receptor-expressing pituitary cell lines. Endocr Rev 1997;18:46-70
18. Conn PM, Crowley WF Jr. Gonadotropin-releasing hormone and its analogs. Annu Rev Med 1994;45:391-405
19. Karten MJ, Rivier JE. Gonadotropin-releasing hormone analog design - Structure-function studies toward the development of agonists and antagonists: Rationale and perspective. Endocr Rev 1986;7:44-66
20. Huirne JAF, Lambalk CB. Gonadotropin-releasing-hormone-receptor antagonists. Lancet 2001;358:1793-1803
21. Schally AV. Luteinizing hormone-releasing hormone analogs: Their impact on the control of tumorigenesis. Peptides 1999;20:1247-1262
22. Bajusz S, Kovacs M, Gazdag M, et al. Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects. Proc Natl Acad Sci U S A 1988;85:1637-1641
23. Ljungqvist A, Feng DM, Hook W, Shen ZX, Bowers C, Folkers K. Antide and related antagonists of luteinizing hormone release with long action and oral activity. Proc Natl Acad Sci U S A 1988;85:8236-8240
24. Rivier J, Porter J, Hoeger C, et al. Gonadotropin-releasing hormone antagonists with N omega-triazolylornithine, -lysine, or -p-aminophenylalanine residues at positions 5 and 6. J Med Chem 1992;35:4270-4278
25. Nestor JJ Jr, Tahilramani R, Ho TL, Goodpasture JC, Vickery BH, Ferrandon P. Potent gonadotropin releasing hormone antagonists with low histamine-releasing activity. J Med Chem 1992;35:3942-3948
26. Garnick MB, Campion M. Abarelix Depot, a GnRH antagonist, v LHRH superagonists in prostate cancer: Differential effects on follicle-stimulating hormone. Abarelix Depot study group. Mol Urol 2000;4:275-277
27. Cook T, Sheridan WP. Development of GnRH antagonists for prostate cancer: New approaches to treatment. Oncologist 2000;5:162-168
28. Brus L, Lambalk CB, de Koning J, Helder MN, Janssens RM, Schoemaker J. Specific gonadotrophin-releasing hormone analogue binding predominantly in human luteinized follicular aspirates and not in human pre-ovulatory follicles. Hum Reprod 1997;12:769-773
29. Raga F, Casan EM, Kruessel J, Wen Y, Bonilla-Musoles F, Polan ML. The role of gonadotropin-releasing hormone in murine preimplantation embryonic development. Endocrinology 1999;140:3705-3712
30. Lahat E, Raziel A, Friedler S, Schieber-Kazir M, Ron-El R. Long-term follow-up of children born after inadvertent administration of a gonadotrophin-releasing hormone agonist in early pregnancy. Hum Reprod 1999;14:2656-2660
31. The Ganirelix Dose-Finding Study Group. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Hum Reprod 1990; 13:3023-3031
32. Kol S, Lightman A, Hillensjo T, et al. High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles. Hum Reprod 1999;14:2242-2244
33. Anik ST, McRae G, Nerenberg C, et al. Nasal absorption of nafarelin acetate, the decapeptide [D-Nal 6)] LHRH, in rhesus monkeys I. J Pharm Sci 1984;73:684-685
34. Holland FJ, Fishman L, Costigan DC, Luna L, Leeder S. Pharmacokinetic characteristics of the gonadotropin-releasing hormone analog D-Ser(TBU)-6EA-10 luteinizing hormone-releasing hormone (buserelin) after subcutaneous and intranasal administration in children with central precocious puberty. J Clin Endocrinol Metab 1986;63:1065-1070
35. Broekmans FJ, Bernardus RE, Berkhout G, Schoemaker J. Pituitary and ovarian suppression after early follicular and midluteal administration of a LHRH agonist in a depot formulation: Decapeptyl CR. Gynecol Endocrinol 1992;6:153-161
36. Porcu E, Dal Prato L, Seracchloli R, Fabbri R, Longhi M, Flamigni C. Comparison between depot and standard release triptoreline in in vitro fertilization: Pituitary sensitivity, luteal function, pregnancy outcome, and perinatal results. Fertil Steril 1994;62:126-132
37. Porcu E, Filicori M, Dal Prato L, et al. Comparison between depot leuprorelin and daily buserelin in IVF. J Assist Reprod Genet 1995;12:15-19
38. Devreker F, Govaerts I, Bertrand E, van den BM, Gervy C, Englert Y. The long-acting gonadotropin-releasing hormone analogues impaired the implantation rate. Fertil Steril 1996;65:122-126
39. Fujii S, Sato S, Fukui A, Kimura H, Kasai G, Saito Y. Continuous administration of gonadotrophin-releasing hormone agonist during the luteal phase in IVF. Hum Reprod 2001; 16:1671-1675
40. Oppenheim DS, Bikkal H, Crowley WF Jr, Klibanski A. Effects of chronic GnRH analogue administration on gonadotrophin and alpha-subunit secretion in post-menopausal women. Clin Endocrinol (Oxf) 1992;36:559-564
41. Winslow KL, Gordon K, Williams RF, Hodgen GD. Interval required for gonadotropin-releasing hormone-agonist-induced down regulation of the pituitary in cynomolgus monkeys and duration of the refractory state. Fertil Steril 1992;58:1209-1214
42. Sungurtekin U, Jansen RP. Profound luteinizing hormone suppression after stopping the gonadotropin-releasing hormone-agonist leuprolide acetate. Fertil Steril 1995;63:663-665
43. Fujii S, Sagara M, Kudo H, Kagiya A, Sato S, Saito Y. A prospective randomized comparison between long and discontinuous-long protocols of gonadotropin-releasing hormone agonist for in vitro fertilization. Fertil Steril 1997;67:1166-1168
44. Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GB Jr. Increased final height in precocious puberty after long-term treatment with LHRH agonists: The National Institutes of Health experience. J Clin Endocrinol Metab 2001;86:4711-4716
45. Oerter KE, Manasco P, Barnes KM, Jones J, Hill S, Cutler GB Jr. Adult height in precocious puberty after long-term treatment with deslorelin. J Clin Endocrinol Metab 1991; 73:1235-1240
46. Palmert MR, Mansfield MJ, Crowley WF Jr, Crigler JF Jr, Crawford JD, Boepple PA. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty. J Clin Endocrinol Metab 1999;84:4480-4488
47. Schlegel PN, Kuzma P, Frick J, et al. Effective long-term androgen suppression in men with prostate cancer using a hydrogel implant with the GnRH agonist histrelin. Urology 2001;58:578-582
48. Chertin B, Spitz IM, Lindenberg T, et al. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer. J Urol 2000;163:838-844
49. Spitz IM, Chertin B, Lindenberg T, Farkas A. Long-acting gonadotropin-releasing hormone implant to maintain medical castration for two years in men with prostate cancer [letter]. N Engl J Med 1999;340:1439
50. Gonen Y, Dirnfeld M, Goldman S, Koifman M, Abramovici H. The use of long-acting gonadotropin-releasing hormone agonist (GnRH-a; decapeptyl) and gonadotropins versus short-acting GnRH-a (buserelin) and gonadotropins before and during ovarian stimulation for in vitro fertilization (IVF). J In Vitro Fert Embryo Transf 1991;8:254-259
51. Balasch J, Jove IC, Moreno V, Civico S, Puerto B, Vanrell JA. The comparison of two gonadotropin-releasing hormone agonists in an in vitro fertilization program. Fertil Steril 1992; 58:991-994
52. Penzias AS, Shamma FN, Gutmann JN,Jones EE, DeCherney AH, Lavy G. Nafarelin versus leuprolide in ovulation induction for in vitro fertilization: A randomized clinical trial. Obstet Gynecol 1992;79:739-742
53. Tapanainen J, Hovatta O, Juntunen K, et al. Subcutaneous goserelin versus intranasal buserelin for pituitary down-regulation in patients undergoing IVF: A randomized comparative study. Hum Reprod 1993;8:2052-2055
54. Dantas ZN, Vicino M, Balmaceda JP, Asch RH, Stone SC. Comparison between nafarelin and leuprolide acetate for in vitro fertilization: Preliminary clinical study. Fertil Steril 1994;61:705-708
55. Goldman JA, Dicker D, Feldberg D, Ashkenazi J, Voliowich I. A prospective randomized comparison of two gonadotrophin-releasing hormone agonists, nafarelin acetate and buserelin acetate, in in-vitro fertilization-embryo transfer. Hum Reprod 1994;9:226-228
56. Lockwood GM, Pinkerton SM, Barlow DH. A prospective randomized single-blind comparative trial of nafarelin acetate with buserelin in long-protocol gonadotrophin-releasing hormone analogue controlled in-vitro fertilization cycles. Hum Reprod 1995;10:293-298
57. Oyesanya OA, Teo SK, Quah E, Abdurazak N, Lee FY, Cheng WC. Pituitary down-regulation prior to in-vitro fertilization and embryo transfer: A comparison between a single dose of Zoladex depot and multiple daily doses of Suprefact. Hum Reprod 1995;10:1042-1044
58. Tanos V, Friedler S, Shushan A, Strauss N, Hetsroni I, Lewin A. Comparison between nafarelin acetate and D-Trp6-LHRH for temporary pituitary suppression in in vitro fertilization (IVF) patients: A prospective crossover study. J Assist Reprod Genet 1995;12:715-719
59. Avrech OM, Goldman GA, Pinkas H, et al. Intranasal nafarelin versus buserelin (short protocol) for controlled ovarian hyperstimulation before in vitro fertilization: A prospective clinical trial. Gynecol Endocrinol 1996;10:165-170
60. Corson SL, Gutmann JN, Batzer FR, Gocial B. A double-blind comparison of nafarelin and leuprolide acetate for down-regulation in IVF cycles. Int J Fertil Menopausal Stud 1996;41:446-449
61. Westergaard LG, Erb K, Laursen SB, Rex S, Rasmussen PE. Human menopausal gonadotropin versus recombinant follicle-stimulating hormone in normogonadotropic women down-regulated with a gonadotropin-releasing hormone agonist who were undergoing in vitro fertilization and intracytoplasmic sperm injection: A prospective randomized study. Fertil Steril 2001;76:543-549
62. Wong JM, Forrest KA, Snabes SZ, Zhao SZ, Gersh GE, Kennedy SH. Efficacy of nafarelin in assisted reproductive technology: A meta-analysis. Hum Reprod Update 2001;7:92-101
63. Zorn JR, Boyer P, Guichard A. Never on a Sunday: Programming for IVF-ET and GIFT. Lancet 1987;1:385-386
64. Pellicer A, Simon C, Miro F, et al. Ovarian response and outcome of in-vitro fertilization in patients treated with gonadotrophin-releasing hormone analogues in different phases of the menstrual cycle. Hum Reprod 1989;4:285-289
65. Daya S. Gonadotrophin-releasing hormone agonist protocols for pituitary desensitization in in vitro fertilization and gamete intrafallopian transfer cycles (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software; 2000
66. Kondaveeti-Gordon U, Harrison RF, Barry-Kinsella C, Gordon AC, Drudy L, Cottell E. A randomized prospective study of early follicular or midluteal initiation of long protocol gonadotropin-releasing hormone in an in vitro fertilization program. Fertil Steril 1996;66:582-586
67. Ron-El R, Herman A, Golan A, van der Ven H, Caspi E, Diedrich K. The comparison of early follicular and midluteal administration of long-acting gonadotropin-releasing hormone agonist. Fertil Steril 1990;54:233-237
68. San Roman GA, Surrey ES, Judd HL, Kerin JF. A prospective randomized comparison of luteal phase versus concurrent follicular phase initiation of gonadotropin-releasing hormone agonist for in vitro fertilization. Fertil Steril 1992;58:744-749
69. Chang SY, Lee CL, Wang ML, et al. No detrimental effects in delaying initiation of gonadotropin administration after pituitary desensitization with gonadotropin-releasing hormone agonist. Fertil Steril 1993;59:183-186
70. Abdalla HI, Baber RJ, Leonard T, et al. Timed oocyte collection in an assisted conception programme using GnRH analogue. Hum Reprod 1989;4:927-930
71. Dimitry ES, Oskarsson T, Conaghan J, Margara R, Winston RM. Beneficial effects of a 24 h delay in human chorionic gonadotrophin administration during in-vitro fertilization treatment cycles. Hum Reprod 1991;6:944-946
72. Tan SL, Brinsden P. The use of luteinising hormone releasing hormone agonists for ovarian stimulation in assisted reproductive technology. Ann Acad Med Singapore 1992;21:504-509
73. Tan SL. Luteinizing hormone-releasing hormone agonists for ovarian stimulation in assisted reproduction. Curr Opin Obstet Gynecol 1994;6:166-172
74. Gonen Y, Jacobson W, Casper RF. Gonadotropin suppression with oral contraceptives before in vitro fertilization. Fertil Steril 1990;53:282-287
75. Kemeter P, Feichtinger W. Experience with a new fixed-stimulation-protocol without hormone determinations for programmed oocyte retrieval for in-vitro fertilization. Hum Reprod 1989;4:53-58
76. Patton PE, Burry KA, Wolf DP, Kiessling AA, Craemer MJ. The use of oral contraceptives to regulate oocyte retrieval. Fertil Steril 1988;49:716-718
77. Templeton A, van Look P, Lumsden MA, et al. The recovery of pre-ovulatory oocytes using a fixed schedule of ovulation induction and follicle aspiration. Br J Obstet Gynaecol 1984;91:148-154
78. Jenkins JM. Cyst formation. Hum Reprod 1995;10:3079-3080
79. Keltz MD, Jones EE, Duleba AJ, Polcz T, Kennedy K, Olive DL. Baseline cyst formation after luteal phase gonadotropin-releasing hormone agonist administration is linked to poor in vitro fertilization outcome. Fertil Steril 1995;64:568-572
80. Feldberg D, Ashkenazi J, Dicker D, et al. Ovarian cyst formation: A complication of gonadotropin-releasing hormone agonist therapy. Fertil Steril 1989;51:42-45
81. Biljan MM, Mahutte NG, Dean N, Hemmings R, Bissonnette F, Tan SL. Pretreatment with an oral contraceptive is effective in reducing the incidence of functional ovarian cyst formation during pituitary suppression by gonadotropin-releasing hormone analogues. J Assist Reprod Genet 1998; 15:599-604
82. Serafini P, Stone B, Kerin J, Batzofin J, Quinn P, Marrs RP. An alternate approach to controlled ovarian hyperstimulation in "poor responders": Pretreatment with a gonadotropin-releasing hormone analog. Fertil Steril 1988;49:90-95
83. Damario MA, Barmat L, Liu HC, Davis OK, Rosenwaks Z. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients. Hum Reprod 1997;12:2359-2365
84. Barriere P, Lopes P, Boiffard JP, et al. Use of GnRH analogues in ovulation induction for in vitro fertilization: Benefit of a short administration regimen. J In Vitro Fert Embryo Transf 1987;4:64-65
85. Smitz J, Bollen N, Camus M, Devroey P, Wisanto A, Van Steirteghem AC. Short-term use of buserelin in combination with human menopausal gonadotrophins for ovarian stimulation for in-vitro fertilization in endocrinologically normal women. Hum Reprod 1990;5:157-162
86. Acharya U, Irvine S, Hamilton M, Templeton A. Prospective study of short and ultrashort regimens of gonadotropin-releasing hormone agonist in an in vitro fertilization program. Fertil Steril 1992;58:1169-1173
87. Howles CM, Macnamee MC, Edwards RG. Short term use of an LHRH agonist to treat poor responders entering an in-vitro fertilization programme. Hum Reprod 1987;2:655-656
88. Macnamee MC, Howles CM, Edwards RG, Taylor PJ, Elder KT. Short-term luteinizing hormone-releasing hormone agonist treatment: Prospective trial of a novel ovarian stimulation regimen for in vitro fertilization. Fertil Steril 1989;52:264-269
89. Martikainen H, Ronnberg L, Tapanainen J, Puistola U, Orava M, Kauppila A. Endocrine responses to gonadotrophins after LHRH agonist administration on cycle days 1-4: Prevention of premature luteinization. Hum Reprod 1990;5:246-249
90. Sharma V, Williams J, Collins W, Riddle A, Mason B, Whitehead M. The sequential use of a luteinizing hormone-releasing hormone (LH-RH) agonist and human menopausal gonadotropins to stimulate folliculogenesis in patients with resistant ovaries. J In Vitro Fert Embryo Transf 1988;5:38-42
91. Corson SL, Batzer FR, Gocial B, Eisenberg E, Huppert LC, Nelson JR. Leuprolide acetate-prepared in vitro fertilization-gamete intrafallopian transfer cycles: Efficacy versus controls and cost analysis. Fertil Steril 1992;57:601-605
92. de Ziegler D, Cedars MI, Randle D, Lu JK, Judd HL, Meldrum DR. Suppression of the ovary using a gonadotropin releasing-hormone agonist prior to stimulation for oocyte retrieval. Fertil Steril 1987;48:807-810
93. Pantos K, Meimeth-Damianaki T, Vaxevanoglou T, Kapetanakis E. Prospective study of a modified gonadotropin-releasing hormone agonist long protocol in an in vitro fertilization program. Fertil Steril 1994;61:709-713
94. Smitz J, Erard P, Camus M, et al. Pituitary gonadotrophin secretory capacity during the luteal phase in superovulation using GnRH-agonists and HMG in a desensitization or flare-up protocol. Hum Reprod 1992;7:1225-1229
95. Smitz J, Van Den AE, Bollen N, et al. The effect of gonadotrophin-releasing hormone (GnRH) agonist in the follicular phase on in-vitro fertilization outcome in normo-ovulatory women. Hum Reprod 1992;7:1098-1102
96. Hazout A, de Ziegler D, Cornel C, Fernandez H, Lelaidier C, Frydman R. Comparison of short 7-day and prolonged treatment with gonadotropin-releasing hormone agonist desensitization for controlled ovarian hyperstimulation. Fertil Steril 1993;59:596-600
97. Yang TS, Tsan SH, Wang BC, Chang SP, Ng HT. The evaluation of a new 7-day gonadotropin-releasing hormone agonist protocol in the controlled ovarian hyperstimulation for in vitro fertilization. J Obstet Gynaecol Res 1996;22:133-137
98. Cedrin-Durnerin I, Bidart JM, Robert P, Wolf JP, Uzan M, Hugues JN. Consequences on gonadotrophin secretion of an early discontinuation of gonadotrophin-releasing hormone agonist administration in short-term protocol for in-vitro fertilization. Hum Reprod 2000;15:1009-1014
99. Tolis G, Ackman D, Stellos A, et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A 1982;79:1658-1662
100. Schoemaker J, Scheele F, Broekmans F, Janssens RM. GnRH agonists: To dose or to overdose? In: Shoham Z, Howles CM, Jacobs HS, eds. Female Infertility Therapy: Current Practice. London: Martin Dunitz; 1999:169-170
101. Janssens RM, Vermeiden JP, Lambalk CB, Schats R, Schoemaker J. Gonadotrophin-releasing hormone agonist dose-dependency of pituitary desensitization during controlled ovarian hyperstimulation in IVF. Hum Reprod 1998;13:2386-2391
102. Lefebvre G. Comparison of two dosages of nafarelin nasal solution with hMG in a short protocol of ovarian stimulation for in vitro fertilization. Nafarelin Recent Advances. London: Parthenon Publishing; 1990:15-21
103. Polson DW, MacLachlan V, Krapez JA, Wood C, Healy DL. A controlled study of gonadotropin-releasing hormone agonist (buserelin acetate) for folliculogenesis in routine in vitro fertilization patients. Fertil Steril 1991;56:509-514
104. Simon A, Benshushan A, Shushan A, et al. A comparison between a standard and reduced dose of D-Trp-6-luteinizing hormone-releasing hormone administered after pituitary suppression for in-vitro fertilization. Hum Reprod 1994;9:1813-1817
105. Sandow J, Donnez J. Clinical pharmakinetics of LHRH analogues. In: Brosens I, Jacobs HS, Runnebaum B, eds. LHRH Analogues in Gynaecology. London: CRC Press-Parthenon Publishers; 2002:17-31
106. Elgendy M, Afnan M, Holder R, et al. Reducing the dose of gonadotrophin-releasing hormone agonist on starting ovarian stimulation: Effect on ovarian response and in-vitro fertilization outcome. Hum Reprod 1998;13:2382-2385
107. Takeuchi S, Minoura H, Shibahara T, Tsuiki Y, Noritaka F, Toyoda N. A prospective randomized comparison of routine buserelin acetate and a decreasing dosage of nafarelin acetate with a low-dose gonadotropin-releasing hormone agonist protocol for in vitro fertilization and intracytoplasmic sperm injection. Fertil Steril 2001;76:532-537
108. Feldberg D, Farhi J, Ashkenazi J, Dicker D, Shalev J, Ben Rafael Z. Minidose gonadotropin-releasing hormone agonist is the treatment of choice in poor responders with high follicle-stimulating hormone levels. Fertil Steril 1994;62:343-346
109. Olivennes F, Righini C, Fanchin R, et al. A protocol using a low dose of gonadotrophin-releasing hormone agonist might be the best protocol for patients with high follicle-stimulating hormone concentrations on day 3. Hum Reprod 1996;11:1169-1172
110. Fleming R, Black WP, Coutts JR. Effects of LH suppression in polycystic ovary syndrome. Clin Endocrinol (Oxf) 1985;23:683-688
111. Dodson WC, Hughes CL, Whitesides DB, Haney AF. The effect of leuprolide acetate on ovulation induction with human menopausal gonadotropins in polycystic ovary syndrome. J Clin Endocrinol Metab 1987;65:95-100
112. Homburg R, Kilborn J, West C, Jacobs HS. Treatment with pulsatile luteinizing hormone-releasing hormone modulates folliculogenesis in response to ovarian stimulation with exogenous gonadotropins in patients with polycystic ovaries. Fertil Steril 1990;54:737-739
113. Weise HC, Fiedler K, Kato K. Buserelin suppression of endogenous gonadotropin secretion in infertile women with ovarian feedback disorders given human menopausal/human chorionic gonadotropin treatment. Fertil Steril 1988;49:399-403
114. Buckler HM, Healy DL, Burger HG. Does gonadotropin suppression result in follicular development in premature ovarian failure? Gynecol Endocrinol 1993;7:123-128
115. Scheele F, Hompes PG, van der MM, Schoute E, Schoemaker J. The effects of a gonadotrophin-releasing hormone agonist on treatment with low dose follicle stimulating hormone in polycystic ovary syndrome. Hum Reprod 1993;8:699-704
116. Vegetti W, Testa G, Ragni G, Parazzini F, Crosignani PG. Ovarian stimulation with low-dose pure follicle-stimulating hormone in polycystic ovarian syndrome anovulatory patients: Effect of long-term pretreatment with gonadotrophin-releasing hormone analogue. Gynecol Obstet Invest 1998; 45:186-189
117. Eshel A, Abdulwahid NA, Armar NA, Adams JM, Jacobs HS. Pulsatile luteinizing hormone-releasing hormone therapy in women with polycystic ovary syndrome. Fertil Steril 1988;49:956-960
118. Filicori M, Flamigni C, Dellai P, et al. Treatment of anovulation with pulsatile gonadotropin-releasing hormone: Prognostic factors and clinical results in 600 cycles. J Clin Endocrinol Metab 1994;79:1215-1220
119. Shoham Z, Homburg R, Jacobs HS. Induction of ovulation with pulsatile GnRH. Baillieres Clin Obstet Gynaecol 1990;4:589-608
120. Hughes E, Collins J, Vandekerckhove P. Gonadothrophin-releasing hormone analogue as an adjunct to gonadotropin therapy for clomiphene-resistant polycystic ovarian syndrome (Cochrane review). In: The Cochrane Library, Issue 4. Oxford: Update Software; 2002
121. Dor J, Shulman A, Levran D, Ben Rafael Z, Rudak E, Mashiach S. The treatment of patients with polycystic ovarian syndrome by in-vitro fertilization and embryo transfer: A comparison of results with those of patients with tubal infertility. Hum Reprod 1990;5:816-818
122. Homburg R, Berkowitz D, Levy T, Feldberg D, Ashkenazi J, Ben Rafael Z. In vitro fertilization and embryo transfer for the treatment of infertility associated with polycystic ovary syndrome. Fertil Steril 1993;60:858-863
123. MacDougall MJ, Tan SL, Balen A, Jacobs HS. A controlled study comparing patients with and without polycystic ovaries undergoing in-vitro fertilization. Hum Reprod 1993; 8:233-237
124. Fleming R, Coutts JR. LHRH analogues for ovulation induction, with particular reference to polycystic ovary syndrome. Baillieres Clin Obstet Gynaecol 1988;2:677-687
125. Abdalla HI, Ahuja KK, Leonard T, Morris NN, Honour JW, Jacobs HS. Comparative trial of luteinizing hormone-releasing hormone analog/human menopausal gonadotropin and clomiphene citrate/human menopausal gonadotropin in an assisted conception program. Fertil Steril 1990;53:473-478
126. Jacobs HS. Polycystic ovaries and polycystic ovary syndrome. Gynecol Endocrinol 1987;1:113-131
127. Ben Rafael Z, Bider D, Dan U, Zolti M, Levran D, Mashiach S. Combined gonadotropin releasing hormone agonist/human menopausal gonadotropin therapy (GnRH-a/hMG) in normal, high, and poor responders to hMG. J In Vitro Fert Embryo Transf 1991;8:33-36
128. Jenkins JM, Davies DW, Devonport H, et al. Comparison of "poor" responders with "good" responders using a standard buserelin/human menopausal gonadotrophin regime for in-vitro fertilization. Hum Reprod 1991;6:918-921
129. Land JA, Yarmolinskaya MI, Dumoulin JC, Evers JL. High-dose human menopausal gonadotropin stimulation in poor responders does not improve in vitro fertilization outcome. Fertil Steril 1996;65:961-965
130. Muasher SJ. Treatment of low responders. J Assist Reprod Genet 1993;10:112-114
131. Padilla SL, Dugan K, Maruschak V, Shalika S, Smith RD. Use of the flare-up protocol with high dose human follicle stimulating hormone and human menopausal gonadotropins for in vitro fertilization in poor responders. Fertil Steril 1996;65:796-799
132. Tasdemir M, Tasdemir I, Kodama H, Fukuda J, Tanaka T Short protocol of gonadotropin releasing hormone agonist administration gave better results in long protocol poor-responders in IVF-ET. J Obstet Gynaecol Res 1996;22:73-77
133. Yang JH, Wu MY, Chao KH, Chen SU, Ho HN, Yang YS. Long GnRH-agonist protocol in an IVF program: Is it appropriate for women with normal FSH levels and high FSH/LH ratios? J Reprod Med 1997;42:663-668
134. Gelety TJ, Pearlstone AC, Surrey ES. Short-term endocrine response to gonadotropin-releasing hormone agonist initiated in the early follicular, midluteal, or late luteal phase in normally cycling women. Fertil Steril 1995;64:1074-1080
135. Loumaye E, Vankrieken L, Depreester S, Psalti I, De Cooman S, Thomas K. Hormonal changes induced by short-term administration of gonadotropin-releasing hormone agonist during ovarian hyperstimulation for in vitro fertilization and their consequences for embryo development. Fertil Steril 1989;51:105-111
136. Fasouliotis SJ, Simon A, Laufer N. Evaluation and treatment of low responders in assisted reproductive technology: A challenge to meet. J Assist Reprod Genet 2000;17:357-373
137. Scott RT, Navot D. Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization. Fertil Steril 1994;61:880-885
138. Fisch B, Royburt M, Pinkas H, et al. Augmentation of low ovarian response to superovulation before in vitro fertilization following priming with contraceptive pills. Isr J Med Sci 1996;32:1172-1176
139. Abramov Y, Elchalal U, Schenker JG. Severe OHSS - An "epidemic" of severe OHSS: A price we have to pay? Hum Reprod 1999;14:2181-2183
140. Forman RG, Frydman R, Egan D, Ross C, Barlow DH. Severe ovarian hyperstimulation syndrome using agonists of gonadotropin-releasing hormone for in vitro fertilization: A European series and a proposal for prevention. Fertil Steril 1990;53:502-509
141. Golan A, Ron-El R, Herman A, Weinraub Z, Soffer Y, Caspi E. Ovarian hyperstimulation syndrome following D-Trp-6 luteinizing hormone-releasing hormone microcapsules and menotropin for in vitro fertilization. Fertil Steril 1988;50:912-916
142. Maroulis GB, Emery M, Verkauf BS, Saphier A, Bernhisel M, Yeko TR. Prospective randomized study of human menotropin versus a follicular and a luteal phase gonadotropin-releasing hormone analog-human menotropin stimulation protocols for in vitro fertilization. Fertil Steril 1991; 55:1157-1164
143. Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: Prevention and treatment. Fertil Steril 1992;58:249-261
144. Gerris J, De Vits A, Joostens M, Van Royen E. Triggering of ovulation in human menopausal gonadotrophin-stimulated cycles: Comparison between intravenously administered gonadotrophin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotrophin (10,000 IU). Hum Reprod 1995;10:56-62
145. Itskovitz J, Boldes R, Levron J, Erlik Y, Kahana L, Brandes JM. Induction of preovulatory luteinizing hormone surge and prevention of ovarian hyperstimulation syndrome by gonadotropin-releasing hormone agonist. Fertil Steril 1991;56:213-220
146. Shalev E, Geslevich Y, Ben Ami M. Induction of pre-ovulatory luteinizing hormone surge by gonadotrophin-releasing hormone agonist for women at risk for developing the ovarian hyperstimulation syndrome. Hum Reprod 1994;9:417-419
147. Aboulghar MA, Mansour RT, Serour GI, Amin Y, Abbas AM, Salah IM. Ovarian superstimulation and intrauterine insemination for the treatment of unexplained infertility. Fertil Steril 1993;60:303-306
148. Chaffkin LM, Nulsen JC, Luciano AA, Metzger DA. A comparative analysis of the cycle fecundity rates associated with combined human menopausal gonadotropin (hMG) and intrauterine insemination (IUI) versus either hMG or IUI alone. Fertil Steril 1991;55:252-257
149. Cohlen BJ, Vandekerckhove P, te Velde ER, Habbema JD. Timed intercourse versus intra-uterine insemination with or without ovarian hyperstimulation for subfertility in men. (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software; 2002
150. DiMarzo SJ, Kennedy JF, Young PE, Hebert SA, Rosenberg DC, Villanueva B. Effect of controlled ovarian hyperstimulation on pregnancy rates after intrauterine insemination. Am J Obstet Gynecol 1992;166:1607-1612
151. Nulsen JC, Walsh S, Dumez S, Metzger DA. A randomized and longitudinal study of human menopausal gonadotropin with intrauterine insemination in the treatment of infertility. Obstet Gynecol 1993;82:780-786
152. Peterson CM, Hatasaka HH, Jones KP, Poulson AM Jr, Carrell DT, Urry RL. Ovulation induction with gonadotropins and intrauterine insemination compared with in vitro fertilization and no therapy: A prospective, nonrandomized, cohort study and meta-analysis. Fertil Steril 1994;62:535-544
153. Dodson WC, Haney AF. Controlled ovarian hyperstimulation and intrauterine insemination for treatment of infertility. Fertil Steril 1991;55:457-467
154. Sengoku K, Tamate K, Takaoka Y, Morishita N, Ishikawa M. A randomized prospective study of gonadotrophin with or without gonadotrophin-releasing hormone agonist for treatment of unexplained infertility. Hum Reprod 1994;9:1043-1047
155. Kim CH, Cho YK, Mok JE. Simplified ultralong protocol of gonadotrophin-releasing hormone agonist for ovulation induction with intrauterine insemination in patients with endometriosis. Hum Reprod 1996;11:398-402
156. Olivennes F, Alvarez S, Bouchard P, Fanchin R, Salat-Baroux J, Frydman R. Thet use of a GnRH antagonist (cetrorelix) in a single dose protocol in IVF-embryo transfer: A dose finding study of 3 versus 2 mg. Hum Reprod 1998; 13:2411-2414
157. Diedrich K, Diedrich C, Santos E, et al. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist cetrorelix during ovarian stimulation. Hum Reprod 1994;9:788-791
158. The Ganirelix Dose-Finding Study Group. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon). Hum Reprod 1998; 13:3023-3031
159. Obruca A, Fischl F, Huber J. Programming oocyte retrieval using oral contraceptive pretreatment before ovarian stimulation with a GnRH antagonist (Cetrotide) protocol. Hum Reprod 2001;16(Abstract book 1):89
160. Naether OGJ, Sterzik K, Strehler E. Cetrotide and Gonal-F in IVF/ICSI patients receiving oral contraceptives for cycle programming prior to IVF/ICSI. Gynecol Endocrinol 2001; 15(suppl 1):12
161. Van Loenen ACD, Huirne JAF, Schats R, Donnez J, Lambalk CB. An open label multicentre randomised parallel controlled phase II study to assess the feasibility of a new programming regimen using an oral contraceptive prior to the administration of recombinant FSH and an GnRH-antagonist in patients undergoing an ART (IVF/ICSI)-treatment. Hum Reprod 2001;16(Abstract book 1):144
162. de Jong D, Macklon NS, Fauser BC. A pilot study involving minimal ovarian stimulation for in vitro fertilization: Extending the "follicle-stimulating hormone window" combined with the gonadotropin-releasing hormone antagonist cetrorelix. Fertil Steril 2000;73:1051-1054
163. Rongieres-Betrrand C, Olivennes F, Righini C, et al. Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (cetrorelix): A pilot study with minimal stimulation. Hum Reprod 1999;14:683-688
164. Albano C, Smitz J, Camus M, Riethmuller-Winzen H, Van Steirteghem A, Devroey P. Comparison of different doses of gonadotropin-releasing hormone antagonist cetrorelix during controlled ovarian hyperstimulation. Fertil Steril 1997; 67:917-922
165. Gordon K, Danforth DR, Williams RF, Hodgen GD. New trends in combined use of gonadotropin-releasing hormone antagonists with gonadotropins or pulsatile gonadotropin-releasing hormone in ovulation induction and assisted reproductive technologies. Curr Opin Obstet Gynecol 1992;4:690-696
166. Dubourdieu S, Le Nestour E, Spitz IM, Charbonnel B, Bouchard P. The combination of gonadotrophin-releasing hormone (GnRH) antagonist and pulsatile GnRH normalizes luteinizing hormone secretion in polycystic ovarian disease but fails to induce follicular maturation. Hum Reprod 1993;8:2056-2060
167. de Jong D, Macklon NS, Mannaerts BM, Coelingh Bennink HJ, Fauser BC. High dose go nadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization. Hum Reprod 1998;13:573-575
168. Albano C, Felberbaum RE, Smitz J, et al. Ovarian stimulation with HMG: Results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod 2000;15:526-531
169. Borm G, Mannaerts B. The European Orgulatran Study Group. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: Results of a controlled, randomized, multicentre trial. Hum Reprod 2000;15:1490-1498
170. The European and Middle East Orgulatran Study Group. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod 2001;16:644-651
171. Fluker M, Grifo J, Leader A, et al. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 2001;75:38-45
172. Craft I, Gorgy A, Hill J, Menon D, Podsiadly B. Will GnRH antagonists provide new hope for patients considered "difficult responders" to GnRH agonist protocols? Hum Reprod 1999;14:2959-2962
173. Nikolettos N, al Hasani S, Felberbaum R, et al. Gonadotropin-releasing hormone antagonist protocol: A novel method of ovarian stimulation in poor responders. Eur J Obstet Gynecol Reprod Biol 2001;97:202-207
174. Akman MA, Erden HF, Tosun SB, Bayazit N, Aksoy E, Bahceci M. Comparison of agonistic flare-up-protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: Results of a prospective randomized trial. Hum Reprod 2001;16:868-870
175. Akman MA, Erden HF, Tosun SB, Bayazit N, Aksoy E, Bahceci M. Addition of GnRH antagonist in cycles of poor responders undergoing IVF. Hum Reprod 2000;15:2145-2147
176. Ragni G, Vegetti W, Baroni E, et al. Comparison of luteal phase profile in gonadotrophin stimulated cycles with or without a gonadotrophin-releasing hormone antagonist. Hum Reprod 2001;16:2258-2262
177. Olivennes F, Belaisch-Allart J, Emperaire JC, et al. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril 2000;73:314-320
178. Al-Inany H, Aboulghar M. Gonadotrophin-releasing hormone antagonists for assisted conception (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software; 2002
179. Ashton WT, Sisco RM, Kieczykowski GR, et al. Orally bioavailable, indole-based nonpeptide GnRH receptor antagonists with high potency and functional activity. Bioorg Med Chem Lett 1999;9:2597-2602